Historical CMC projects that Eviva Pharma have worked on include experience of numerous dosage forms, from pre-clinical to late phase products, and as such offer consultancy that is broad based.

Further details of these historical CMC projects can be found below.

PRE-CLINICAL
Type of Compound	Dose Form	Activity
Synthetic compound	Oral	Analytical
Kinase inhibitor	IV	Analytical
Kallikrein inhibitor	Oral	Analytical
PHASE I
Type of Compound	Dose Form	Activity
Monoclonal antibody	IV, Aqueous	Analytical
Tetra peptide	Injection, Aqueous	Analytical
Monoclonal antibody	IV, Aqueous	Analytical
Monoclonal antibody	IV, Aqueous	Analytical
Hsp inhibitor	IV, Lyophilised	Formulation development/Analytical
Peptide	SC, Aqueous	Formulation development
Monoclonal antibody	IV, Aqueous	Analytical
Killed bacterial vaccine	Oral, Suspension	Formulation development/Analytical
T-cell inhibitor	Oral	Analytical
Thrombin inhibitor	IV	Formulation development
PHASE II
Type of Compound	Dose Form	Activity
Monoclonal antibody	IV, Aqueous	Analytical
Killed bacterial vaccine	Oral, Suspension	Formulation development/Analytical
Conjugated angiotensin peptide	Injection, Aqueous	Analytical
Synthetic compound derived from plants	IA, Surfactant solution	Formulation development
Synthetic	IV, Aqueous	Formulation development
Synthetic MDR	Oral, soft gel capsule	Formulation development
Synthetic MDR	IV, Co-solvent	Formulation development
PHASE III/IV
Type of Compound	Dose Form	Activity
Active metabolite of morphine	IV, Aqueous	Analytical
Cocaine conjugate	Injection, Aqueous	Analytical
PAF antagonist	IV, Aqueous	Formulation development
Synthetic	Oral, Tablet	Expert report
Synthetic phosphodiesterase inhibitor	IV, Co-solvent	Formulation development
Semi synthetic glycopeptide	IV, Lyophilised	Formulation development
Synthetic	Oral, Tablet	Expert report
MARKETED
Type of Compound	Dose Form	Activity
Anti-venom	IV, Lyophilised	Analytical